Nurasyl Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 12-12-2024
- Paid Up Capital ₹ 0.10 M
as on 12-12-2024
- Company Age 5 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2022)
- Profit 106.22%
(FY 2022)
- Ebitda 106.22%
(FY 2022)
- Net Worth 6.99%
(FY 2022)
- Total Assets -89.58%
(FY 2022)
About Nurasyl Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jignasu Sudani, Tejas Zaveri, and Maulikkumar Sudani serve as directors at the Company.
- CIN/LLPIN
U51909GJ2019PTC110092
- Company No.
110092
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Sep 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Nurasyl Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jignasu Sudani  | Director | 27-Sep-2019 | Current |
| Tejas Zaveri | Director | 01-Mar-2024 | Current |
| Maulikkumar Sudani | Director | 27-Sep-2019 | Current |
Financial Performance of Nurasyl Lifesciences.
Nurasyl Lifesciences Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 106.22% increase in profit. The company's net worth moved up by a moderate rise of 6.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nurasyl Lifesciences?
In 2022, Nurasyl Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Farbe Firma Private LimitedActive 3 years 6 monthsJignasu Sudani and Maulikkumar Sudani are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nurasyl Lifesciences?
Unlock and access historical data on people associated with Nurasyl Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nurasyl Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nurasyl Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
